Intensity Therapeutics is developing INT230-6, a water based cancer treatment injected directly into solid tumors. INTS reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 18 | HC Wainwright & Co. | Maintained | Buy |
Seasonality
How INTS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.
Whale Options Flow
90DNo whale options trades in INTS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INTS is in one of them and how their past INTS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered INTS in an article yet. Here's the latest on the wider market.
About Intensity Therapeutics
Intensity Therapeutics is a clinical stage biotechnology company based in Shelton, Connecticut. It is developing INT230-6, a water based treatment that is injected directly into solid tumors. The candidate combines two established chemotherapy drugs, cisplatin and vinblastine sulfate, with a molecule that helps them spread through the tumor. The company is aiming the treatment at patients with solid cancers, such as breast cancer and sarcoma, and it does not yet have an approved product for sale.
- Headquarters
- Shelton, CT